Does Cefuroxime Cover Haemophilus influenzae?
Yes, cefuroxime provides effective coverage against Haemophilus influenzae, including β-lactamase-producing strains, making it a suitable second-generation cephalosporin for respiratory tract infections caused by this pathogen.
Coverage Profile
Cefuroxime demonstrates significantly enhanced activity against β-lactamase-producing H. influenzae compared to first-generation cephalosporins and early second-generation agents like cefaclor 1. The FDA label explicitly lists H. influenzae (including ampicillin-resistant strains) as a covered pathogen for lower respiratory tract infections, meningitis, and septicemia 2.
Clinical Context and Comparative Activity
Respiratory Infections
- Guideline-endorsed use: Multiple national guidelines from 2004-2005 recommend cefuroxime axetil for acute bacterial rhinosinusitis, where H. influenzae is one of the three most common pathogens (along with S. pneumoniae and M. catarrhalis) 1, 3, 1
- Twice-daily dosing advantage: Cefuroxime offers convenient BID administration with significantly enhanced activity against β-lactamase-producing H. influenzae 1
Important Caveat - Relative Potency
While cefuroxime covers H. influenzae, it is less active than third-generation cephalosporins like cefpodoxime 3. The guidelines specifically note that "cefuroxime axetil is less active than cefpodoxime against H. influenzae" 3. This matters clinically when:
- Treating moderate disease
- Managing patients with recent antibiotic exposure (past 4-6 weeks)
- Dealing with areas of high β-lactamase prevalence (approaching 50% of H. influenzae strains) 1
Resistance Considerations
β-Lactamase Production
- Nearly 50% of H. influenzae in most geographic areas produce β-lactamase 1
- Cefuroxime maintains activity against these strains, unlike ampicillin or amoxicillin alone
- Research confirms susceptibility rates of 85.4% for β-lactamase-positive strains 4
Non-β-Lactamase Mediated Resistance
Critical pitfall: Rare but documented cefuroxime resistance can occur through altered penicillin-binding proteins (PBPs), particularly PBPs 4 and 5, even in β-lactamase-negative strains 5, 6. Specific mutations in the ftsI gene (notably S357N substitution) can confer resistance 6. This mechanism led to documented treatment failure in H. influenzae meningitis despite standard dosing 5.
Recent molecular data shows that 61.5% of multidrug-resistant non-typeable H. influenzae isolates demonstrated cefuroxime resistance through genetic variations in ftsI and lpoA 7.
Dosing for Adequate Coverage
Adults
- Standard: 750 mg IV/IM every 8 hours
- Severe infections: 1.5 grams every 8 hours 2
Pediatrics
- Meningitis: 200-250 mg/kg/day divided every 6-8 hours 8
- Respiratory infections: Follow weight-based dosing per guidelines 9
CSF Penetration
When treating H. influenzae meningitis, cefuroxime achieves therapeutic CSF concentrations of 6.4 ± 1.7 mcg/mL at 2 hours post-dose, adequate for susceptible strains 2, 8.
Clinical Decision Algorithm
Use cefuroxime for H. influenzae when:
- Treating mild-to-moderate respiratory infections in patients without recent antibiotic exposure
- β-lactam allergy precludes use of amoxicillin-clavulanate (use cephalosporin for non-Type I reactions)
- Oral suspension palatability is not a primary concern (cefuroxime axetil suspension tastes poor) 1
Consider alternatives (cefpodoxime, cefdinir, or respiratory fluoroquinolones) when:
- Patient has moderate disease or recent antibiotic use (past 4-6 weeks) 3
- Higher H. influenzae coverage is needed
- Treatment failure occurs on cefuroxime
Avoid cefuroxime when:
- First-generation cephalosporins or cefaclor would be considered (inadequate H. influenzae coverage) 1
- Documented PBP-mediated resistance exists (rare but serious)
The inoculum effect can significantly impact cefuroxime activity against H. influenzae, emphasizing the importance of adequate dosing 10.